Aug. 22 at 12:07 PM
Wells Fargo⬆️
$IONS $82 wass
$77/Overweight~sees momentum in
$IONS's commercial and near-commercial programs in the near term.
$TAK $BCRX $PHGUF $KALV $NTLA
Piper Sandler⬆️
$IONS' PT to
$65 from
$62 and reiterated at Overweight: Remain Overweight rated on
$IONS shares following the on-time FDA approval for Dawnzera (donidalorsen) in hereditary angioedema (HAE) in adult and pediatric patients 12+, marking the company's second independent product approval/launch.
The label is largely in-line with expectations, including both Q4W and Q8W dosing intervals and, not surprisingly in our view, switching data was left off (but has been published and can be promoted).
We're encouraged by
$IONS' commentary around the experienced sales team in allergy and immunology (with direct HAE experience) and other commercial preparations, and based on HAE primarily being a switch market, we expect gradual but broad uptake. Remain buyers with a new
$65 PT.
